Skip to main content

Table 5 Multivariable analysis of prognostic factors of 68 NPC patients with positive postoperative pathological results

From: The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study

Variable

PFS

OS

DMFS

LRRFS

LRFS

RRFS

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Age

0.948 (0.458–1.962)

0.885

1.365 (0.501–3.719)

0.543

0.505 (0.164–1.555)

0.234

0.750 (0.336–1.676)

0.483

0.662 (0.231–1.895)

0.442

1.097 (0.412–2.917)

0.853

Sex

0.866 (0.401–1.871)

0.715

0.506 (0.160–1.600)

0.246

0.652 (0.192–2.208)

0.492

0.568 (0.248–1.302)

0.182

0.595 (0.202–1.752)

0.346

0.489 (0.176–1.360)

0.171

T stage

2.733 (1.139–6.557)

0.024

4.523 (1.240–16.501)

0.022

11.418 (2.406–54.182)

0.002

1.616 (0.633–4.126)

0.315

1.473 (0.441–4.923)

0.529

2.985 (0.900–9.894)

0.074

N stage

2.070 (0.555–7.726)

0.279

2.852 (0.564–14.409)

0.205

8.385 (1.213–57.978)

0.031

1.380 (0.339–5.617)

0.653

2.054 (0.303–13.919)

0.461

2.979 (0.528–16.798)

0.216

Clinical stage

0.593 (0.240–1.463)

0.256

1.183 (0.369–3.790)

0.777

0.361 (0.086–1.515)

0.164

0.696 (0.285–1.697)

0.425

0.467 (0.132–1.651)

0.237

0.621 (0.192–2.008)

0.426

EBV DNA before first treatment

1.166 (0.553–2.459)

0.687

0.812 (0.287–2.295)

0.695

1.296 (0.287–0.423)

0.650

1.762 (0.770–4.033)

0.180

0.868 (0.300–2.510)

0.793

3.631 (1.013–13.019)

0.048

Preoperative EBV DNA

1.589 (0.768–3.290)

0.212

3.501 (1.075–11.398)

0.037

2.051 (0.688–6.119)

0.197

1.575 (0.732–3.389)

0.246

2.588 (0.926–7.234)

0.070

1.827 (0.684–4.882)

0.229

Treatment for NPC

1.341 (0.800–2.247)

0.266

1.621 (0.684–3.845)

0.273

3.367 (1.081–10.489)

0.036

1.120 (0.657–1.910)

0.677

0.840 (0.461–1.531)

0.569

2.184 (0.874–5.459)

0.095

  1. NPC nasopharyngeal carcinoma, PFS progression-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival, LRFS local relapse-free survival, RRFS regional relapse-free survival, HR hazard ratio, CI confidence interval
  2. All variables were transformed into categorical variables. HRs were calculated for age (≥ 45 vs. < 45 years), sex (male vs. female), T stage (3–4 vs. 1–2), N stage (3 vs. 1–2), clinical stage (IV vs. III vs. II), EBV DNA before first treatment (> 4000 vs. ≤ 4000 copies/mL), preoperative EBV DNA (> 0 vs. 0 copy/mL), and treatment for NPC (RT vs. CCRT vs. NAC + CCRT vs. CCRT + AC)